Cullinan Oncology LLC to Develop Novel EBNA1 Inhibitor Discovered by The Wistar Institute

Cullinan Oncology develops high value therapeutics geared towards dramatically improving the standard of care for those living with cancer. The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. They entered into an agreement to accelerate the development of VK-2019, a novel EBNA1 (Epstein-Barr Nuclear Antigen 1).

CAMBRIDGE, Mass. & PHILADELPHIA–Cullinan Oncology, LLC and The Wistar Institute announced agreement to accelerate the development of VK-2019, a novel EBNA1 (Epstein-Barr Nuclear Antigen 1) inhibitor discovered by The Wistar Institute.

VK-2019 will be developed by Cullinan Apollo, a company formed and managed by Cullinan Oncology, LLC. Under the terms of the agreement, The Wistar Institute has granted an exclusive worldwide license for the development and commercialization of the EBNA1 inhibitor to Cullinan Apollo. Wistar has received an up-front license fee and an equity interest in Cullinan Apollo, with the potential to receive additional downstream milestones and royalty payments as the asset progresses.

“We look forward to advancing this highly novel, first-in-class asset into the clinic over the coming weeks,” said Leigh Zawel, CSO, Small Molecules at Cullinan Oncology, LLC. “The Wistar scientists have spent nearly a decade developing this molecule, and we appreciate their confidence in our ability to successfully develop this EBNA1 inhibitor.”

EBV (Epstein-Barr Virus), a well-established driver of various cancers, is critically reliant on the viral DNA-binding factor EBNA1 for viral genome maintenance. This new compound potently inhibits EBNA1 function. In preclinical models of EBV-associated cancer, it eliminated EBV, resulting in tumor growth inhibition. Development of this compound was largely supported by an investment of over U.S. $10 million from Wellcome, a biomedical research charity based in the United Kingdom.

“We are excited to work with the Cullinan Apollo team to embark on the next phase of clinical development of our lead therapeutic candidate for EBV-associated cancers,” said Paul M. Lieberman, Ph.D., Hilary Koprowski, M.D., Endowed Professor, professor and leader of the Gene Expression and Regulation Program, and director of the Center for Chemical Biology and Translational Medicine at The Wistar Institute. “This drug is exemplary of the results of the hard work of my lab – most notably Dr. Troy Messick – together with our committed collaborators at Fox Chase Chemical Diversity Center, Inc. and invaluable input from Wellcome and its advisors. We need exceptional partners to work with us to move our discoveries forward, and this is one example of that.”

Source: Businesswire

Contacts

For Cullinan:
Matt Burke
mburke@nullcullinanoncology.com
+1 603.315.0618

For Wistar:
Tara Yates
tyates@nullwistar.org
+1 215.898.3826